表紙
市場調査レポート

増殖性硝子体網膜症(PVR):パイプライン分析

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 302496
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
増殖性硝子体網膜症(PVR):パイプライン分析 Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016
出版日: 2016年08月17日 ページ情報: 英文 38 Pages
概要

当レポートでは、増殖性硝子体網膜症(PVR)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

増殖性硝子体網膜症(PVR)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Promedior, Inc.
  • RXi Pharmaceuticals Corporation

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy
  • LD-224
  • Oligonucleotide 2 for Age Related Macular Degeneration and Proliferative Vitreoretinopathy
  • Oligonucleotide for Age Related Macular Degeneration and Proliferative Vitreoretinopathy
  • PRM-167
  • RNAi Oligonucleotide to Inhibit CTGF for PVR
  • Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy

最新パイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8363IDB

Summary

Global Markets Direct's, 'Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016', provides an overview of the Proliferative Vitreoretinopathy (PVR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)
  • The report reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects
  • The report assesses Proliferative Vitreoretinopathy (PVR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Proliferative Vitreoretinopathy (PVR) Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Overview 7
  • Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis 8
  • Proliferative Vitreoretinopathy (PVR) - Therapeutics under Development by Companies 9
  • Proliferative Vitreoretinopathy (PVR) - Therapeutics under Investigation by Universities/Institutes 10
  • Proliferative Vitreoretinopathy (PVR) - Pipeline Products Glance 11
  • Early Stage Products 11
  • Proliferative Vitreoretinopathy (PVR) - Products under Development by Companies 12
  • Proliferative Vitreoretinopathy (PVR) - Products under Investigation by Universities/Institutes 13
  • Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development 14
  • Novartis AG 14
  • Promedior, Inc. 15
  • RXi Pharmaceuticals Corporation 16
  • Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment 17
  • Assessment by Monotherapy Products 17
  • Assessment by Target 18
  • Assessment by Mechanism of Action 20
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • LD-224 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • PRM-167 - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • XOMA-089 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • Proliferative Vitreoretinopathy (PVR) - Dormant Projects 32
  • Proliferative Vitreoretinopathy (PVR) - Product Development Milestones 33
  • Featured News & Press Releases 33
  • Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences 33
  • May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform 34
  • May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 35
  • May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 36
  • Appendix 37
  • Methodology 37
  • Coverage 37
  • Secondary Research 37
  • Primary Research 37
  • Expert Panel Validation 37
  • Contact Us 37
  • Disclaimer 38

List of Tables

  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H2 2016 7
  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Number of Products under Investigation by Universities/Institutes, H2 2016 10
  • Comparative Analysis by Early Stage Development, H2 2016 11
  • Products under Development by Companies, H2 2016 12
  • Products under Investigation by Universities/Institutes, H2 2016 13
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, H2 2016 14
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Promedior, Inc., H2 2016 15
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 16
  • Assessment by Monotherapy Products, H2 2016 17
  • Number of Products by Stage and Target, H2 2016 19
  • Number of Products by Stage and Mechanism of Action, H2 2016 21
  • Number of Products by Stage and Route of Administration, H2 2016 22
  • Number of Products by Stage and Molecule Type, H2 2016 24
  • Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H2 2016 32

List of Figures

  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H2 2016 7
  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Assessment by Monotherapy Products, H2 2016 17
  • Number of Products by Targets, H2 2016 18
  • Number of Products by Stage and Targets, H2 2016 18
  • Number of Products by Mechanism of Actions, H2 2016 20
  • Number of Products by Stage and Mechanism of Actions, H2 2016 20
  • Number of Products by Molecule Types, H2 2016 23
  • Number of Products by Stage and Molecule Types, H2 2016 23
Back to Top